VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwAL 2018 | Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response

Immune checkpoint inhibitors are a promising area of therapy, with our understanding of their mechanism of action and the ways in which we can tailor this to better utilize them improving rapidly. In this particularly insightful interview, Naval Daver, MD, of the MD Anderson Cancer Center, Houston, TX, explains the mechanism of action of this therapy and the rationale for its use in acute myeloid leukemia (AML). Dr Daver also highlights the exciting strategy of upregulating PD-1/PD-L1 expression using hypomethylating agents to improve checkpoint inhibitor therapy response. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter